Serious Adverse Events

Database Placebo Tegaserod

Pooled phase II studies 5/151 3.3% 10/519 1.9%

Pooled phase III studies 13/837 1.6% 30/1,679 1.8%

Pooled phase II/III studies 18/988 1.8% 40/2,198 1.8%

Long-term studies 28/675 4.1%

2

Previous slide

Next slide

Back to first slide

View graphic version